Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$4.15M, compared with $38.01M a year earlier. Trailing-twelve-month net income was -$9.47M.

Context

  • Net income amounted to 27.1% of revenue in FY2025, down 39.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$12.99M (-139.7%) for the fiscal year ending Dec 2026, a slowdown from the +138.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.15M-21.7% QoQ
Last fiscal yearDec 2025
$32.69M+138.3% YoY
LTMMar 2026
-$9.47M+39.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-110.9%-302.2%-191.3 pp
1 year+138.3%-139.7%-278.0 pp
3-year CAGR—-39.5%—
5-year CAGR+1.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
32.69M USD
Year-over-year change
+138.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.5% is the 2nd highest of 11, against a peer median of -6.0%.
  • Net income amounts to 40.9% of revenue for ATRA, versus a peer median of 302.7%.
ATRA Competitors
Net Income for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$110M USD+489.6%——
CSBRChampions Oncology, Inc.LTM Jan 2026-$2.28M USD-135.5%+104.7%3.9%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$9.47M USD+39.5%—40.9%
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.13M USD-23.3%—266.1%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24.17M USD+3.2%—339.3%
CLNNClene Inc.LTM Mar 2026-$33.51M USD-15.3%—25009.7%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.23M USD-45.6%——
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M USD-26.1%—44.8%
STROSutro Biopharma, Inc.LTM Mar 2026-$153.6M USD+37.4%—154.2%
Peer median (excluding ATRA) —-6.0%+104.7%302.7%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.